The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol
Abstract
BACKGROUND: Inhibitors of the rate-limiting enzyme of cholesterol biosynthesis, 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase, are now used frequently to treat hypercholesterolemia. We studied the effects of specific inhibition of cholesterol synthesis by one of these agents (pravastatin) on the hepatic metabolism of cholesterol in patients with gallstone disease who were scheduled to undergo cholecystectomy. METHODS: Ten patients were treated with pravastatin (20 mg twice a day) for three weeks before cholecystectomy; 20 patients not treated served as controls. A liver specimen was obtained from each patient at operation, and the activities of rate-determining enzymes in cholesterol metabolism as well as low-density-lipoprotein (LDL)-receptor binding activity were determined. RESULTS: Pravastatin therapy reduced plasma total cholesterol by 26 percent and LDL cholesterol by 39 percent (P less than 0.005). Serum levels of free lathosterol, a precursor of cholesterol whose concentration reflects the rate of cholesterol synthesis in vivo, decreased by 63 percent (P less than 0.005), indicating reduced de novo biosynthesis of cholesterol. Microsomal HMG-CoA reductase activity, when analyzed in vitro in the absence of the inhibitor, was increased 11.8-fold (1344 +/- 311 vs. 105 +/- 14 pmol per minute per milligram of protein in the controls; P less than 0.001). The expression of LDL receptors was increased by 180 percent (P less than 0.005), whereas the activities of cholesterol 7 alpha-hydroxylase (which governs bile acid synthesis) and of acyl-coenzyme A:cholesterol O-acyltransferase (which regulates cholesterol esterification) were unaffected by treatment. CONCLUSIONS: Inhibition of hepatic HMG-CoA reductase by pravastatin results in an increased expression of hepatic LDL receptors, which explains the lowered plasma levels of LDL cholesterol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Snedecor, G. W., & Cochran, W. G. (1967) · Cited by 6,573
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rouser, G., Fleischer, S., & Yamamoto, A. (1970) · Lipids · doi:10.1007/bf02531316 · Cited by 3,274
Cholesterol determination in high-density lipoproteins separated by three different methods.
Lopes-Virella, M. F., Stone, P., Ellis, S., & Colwell, J. A. (1977) · Clinical Chemistry · doi:10.1093/clinchem/23.5.882 · Cited by 1,841
Blankenhorn, D. H. (1987) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1987.03390230069027 · Cited by 1,655
Critical tables for calculating the cholesterol saturation of native bile.
Carey, M. C. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40677-7 · Cited by 794
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 758
Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.13.4124 · Cited by 557
Cited by
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 875
DeBose-Boyd, R. A. (2008) · Cell Research · doi:10.1038/cr.2008.61 · Cited by 391
Pharmacology of competitive inhibitors of HMg-CoA reductase
Corsini, A. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80042-5 · Cited by 277
Importance of growth hormone for the induction of hepatic low density lipoprotein receptors.
Rudling, M., Norstedt, G., Olivecrona, H., Reihnér, E., Gustafsson, J. A., & Angelin, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.6983 · Cited by 269
Self-citationJiang, S.-Y., Li, H., Tang, J.-J., Wang, J., Luo, J., Liu, B., Wang, J.-K., Shi, X.-J., Cui, H.-W., Tang, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07590-3 · Cited by 173
Metadata
- Authors
- Reihnér, E., Rudling, M., Ståhlberg, D., Berglund, L., Ewerth, S., Björkhem, I., Einarsson, K., & Angelin, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1990-07-26
- Volume
- 323
- Issue
- 4
- Pages
- 224-228
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2317657624
- Cited by
- 277
- References
- 36
- FWCI
- 28.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol. https://app.cochat.ai/papers/10.1056/nejm199007263230403
- The paper
- Reihnér, E., Rudling, M., Ståhlberg, D., Berglund, L., Ewerth, S., Björkhem, I., Einarsson, K., & Angelin, B. (1990). Influence of Pravastatin, a Specific Inhibitor of HMG-CoA Reductase, on Hepatic Metabolism of Cholesterol. New England Journal of Medicine. https://doi.org/10.1056/nejm199007263230403
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.